Spectral AI, Inc. 8K

Spectral AI, Inc. announced Q2 2026 results and operational progress, including FDA clearance and commercialization preparations for its DeepView burn diagnostic system, BARDA funding, additional credit facility borrowing, leadership changes, and reiterated 2026 revenue guidance.

On August 11, 2026, Spectral AI, Inc. reported its financial results for the second quarter ended June 30, 2026, highlighting the recent FDA De Novo clearance of its DeepView System for burn indication that enables initial U.S. commercial sales targeted by year-end 2026, the award of $31.7 million of advanced BARDA funding and completion of key Department of Defense/MTEC milestones for its handheld device, the draw of $6.5 million under its Avenue Capital Group credit facility, leadership team expansions including the appointments of a new CFO and CCO, and financial performance characterized by reduced research and development revenue due to contract phase changes, lower gross margins driven by cost-share provisions, higher operating expenses tied to commercialization efforts, narrowed quarterly net loss versus the prior year, and a cash balance of $14.0 million as of June 30, 2026, along with reiterated full-year 2026 revenue guidance of approximately $18.5 million.

Filing Facts

CIK

1833498

Ticker

-

Form

8K

Source Type

sec

Accession

0001213900-26-088341

Alert Tier

7